Table 2 Prognostic factors in ICC patients by univariate analysis.

From: AZGP1 activation by lenvatinib suppresses intrahepatic cholangiocarcinoma epithelial-mesenchymal transition through the TGF-β1/Smad3 pathway

Variables

OS

RFS

HR (95% CI)

P-value

HR (95% CI)

P-value

Age>60, year

1.89 (0.80–4.48)

0.145

1.81 (0.76–4.25)

0.179

Gender

1.39 (0.79–2.2.45)

0.25

1.62 (0.91–2.88)

0.101

HBsAg

0.78 (0.42–1.44)

0.424

0.64 (0.35–1.18)

0.158

TNM Stage III, IV

4.65 (2.40–8.99)

<0.001

4.03 (2.13–7.63)

<0.001

Tumor differentiation

2.23 (1.24–3.99)

0.007

1.79 (1.01–3.21)

0.048

Tumor size > 5.0, cm

1.42 (0.79–2.56)

0.242

1.35 (0.75–2.42)

0.323

Tumor number

1.53 (0.70–3.31)

0.285

1.55 (0.71–3.36)

0.272

Tumor location

1.16 (0.65–2.08)

0.623

1.09 (0.61–1.97)

0.753

Lymph node metastasis

3.91 (1.84–8.29)

<0.001

3.63 (1.74–7.55)

0.001

Vascular invasion

1.71 (0.88–3.32)

0.117

1.68 (0.87–3.27)

0.125

Perineural invasion

1.46 (0.78–2.75)

0.236

1.67 (0.89–3.15)

0.111

AFPå 9, ng/mL

1.59 (0.49–5.19)

0.438

1.24 (0.38–4.01)

0.723

CEAå 5, μg/L

2.25 (1.23–4.13)

0.009

1.97 (1.09–3.59)

0.026

CA19-9å 37, U/mL

1.9 (0.97–3.71)

0.06

2.01 (1.03–3.94)

0.04

AZGP1 level

0.44 (0.22–0.89)

0.021

0.48 (0.24–0.96)

0.038

Diabetes

2.79 (1.38–5.66)

0.004

2.04 (1.04–4.02)

0.039

  1. Bold values indicates statistically significant p values less than 0.05.
Back to article page